Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 10/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5617531 | 1.00 | GRM2 (0.48) | GRM2SIGMAR1F10MAOA | |
| SCHEMBL5618256 | 1.00 | GRM2 (0.48) | GRM2SIGMAR1F10MAOA | |
| SCHEMBL7299828 | 0.93 | GRM2 (0.46) | GRM2SIGMAR1MAOA | |
| SCHEMBL7299836 | 0.93 | GRM2 (0.46) | GRM2SIGMAR1MAOA | |
| SCHEMBL7299934 | 0.92 | GRM2 (0.52) | GRM2SIGMAR1F10MAOA | |
| SCHEMBL7299930 | 0.92 | GRM2 (0.52) | GRM2SIGMAR1F10MAOA | |
| SCHEMBL7301759 | 0.91 | GRM2 (0.46) | GRM2SIGMAR1F10MAOA | |
| SCHEMBL7300066 | 0.91 | GRM2 (0.46) | GRM2SIGMAR1F10MAOA | |
| SCHEMBL7300057 | 0.91 | GRM2 (0.46) | GRM2SIGMAR1F10MAOA | |
| SCHEMBL7304715 | 0.89 | F10 (0.54) | GRM2SIGMAR1F10MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| EP-0657440-B1 | Oxazolidine-2-one derivatives as MAO inhibitors | HOFFMANN LA ROCHE (CH) | 2000-04-05 | — | — | EP | claimed |
| EP-0657440-A1 | Oxazolidine-2-one derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-14 | — | — | EP | claimed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| EP-0657440-B1 | Oxazolidine-2-one derivatives as MAO inhibitors | HOFFMANN LA ROCHE (CH) | 2000-04-05 | — | — | EP | disclosed |
| US-5574055-A | COGNITIVE AND NEURODEGENERATIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0657440-A1 | Oxazolidine-2-one derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | GRM2 808/4885SIGMAR1 1384/4885F10 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.